A phase III, randomized, open-label trial of nivolumab (anti-PD-1; BMS-936558, ONO-4538) versus investigator's choice chemotherapy (ICC) as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer (NSCLC).
David Paul Carbone
Consultant or Advisory Role - Bristol-Myers Squibb; Merck; Roche
Honoraria - Bristol-Myers Squibb; Merck; Roche
Research Funding - Bristol-Myers Squibb
Mark A. Socinski
No relevant relationships to disclose
Allen C. Chen
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Prabhu Bhagavatheeswaran
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Martin Reck
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Pfizer; Roche
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Roche
Luis Paz-Ares
Consultant or Advisory Role - Bristol-Myers Squibb